By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...

Steatotic liver disease affects approximately one tenth of lean adults in the United States, according to data from the ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

Have you been diagnosed with fatty liver disease? Here are the top 10 foods that you must avoid eating right now to control ...

A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver complications ...

A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...

Major barriers in screening for fatty liver disease in patients with HIV included uncertainties about testing, diagnostic ...

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...